Pharma exporters body Pharmexcil has suspended the membership of Maiden Pharmaceuticals, the Delhi-based drugmaker facing a probe after the World Health Organization (WHO) red-flagged four products following the death of 66 children in the West African country The Gambia.
With the Council not receiving any input/report on the adverse events, from the company, the membership of Maiden Pharmaceuticals is being suspended with immediate effect, Pharmaceuticals Export Promotion Council of India Director General Ravi Udaya Bhaskar said.
Suspension of membership means the company will not be entitled to incentives made available by the government under its Market Access initiative. Under the scheme, incentives up to ₹2 crore are extended to a company registering their product with a drug/health regulator abroad. Another benefit the membership provide is a ₹25 lakh one time grant to the MSMEs for implementing the pharmaceutical drug track and trace system, he said.
